Buy Rating for AngioDynamics Driven by New Clinical Trial and Product Synergy
I'm PortAI, I can summarize articles.
Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on AngioDynamics with an $18.00 price target. The rating is driven by a new clinical trial for the AlphaReturn Blood Management System, designed to work with the AlphaVac F18 System, aiming to treat acute pulmonary embolism. The trial's primary completion date is November 2026. The strategic move is expected to drive significant growth for the AlphaVac platform, with projected revenue growth of 41% year-over-year by fiscal year 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments